Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

Roberta P.A. Manzano, Gholam A. Peyman, Palwasha Khan, Petros E. Carvounis, Muhamet Kivilcim, Min Ren, Jonathan C. Lake, Patricia Chévez-Barrios

Research output: Contribution to journalArticlepeer-review

201 Scopus citations


Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

Original languageEnglish (US)
Pages (from-to)804-807
Number of pages4
JournalBritish Journal of Ophthalmology
Issue number6
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)'. Together they form a unique fingerprint.

Cite this